Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients

Molecular Oncology

Volumn 10, Issue 3, 2016, Pages 475-480

  Siravegna, Giulia ^a,b,c   Bardelli, Alberto ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Circulating tumor DNA; Colorectal cancer; Liquid biopsy; Targeted therapy

Indexed keywords

CELL FREE DNA; DNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ALLELE; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL PRACTICE; CLONAL EVOLUTION; COLON CANCER; COLORECTAL CANCER; DNA DETERMINATION; GENOTYPE; HUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD; COLON; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENETICS; GENOTYPING TECHNIQUE; PATHOLOGY; PROCEDURES; RECTUM;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; COLON; COLORECTAL NEOPLASMS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; RECTUM;

EID: 84959178370     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.12.005     Document Type: Review

References (45)

1. Bardelli A., Corso S., Bertotti A., Hobor S., Valtorta E., Siravegna G., Sartore-Bianchi A., Scala E., Cassingena A., Zecchin D., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013, 3:658-673.
2. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 2010, 28:1254-1261.
3. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., Corà D., Di Nicolantonio F., Buscarino M., Petti C., et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011, 1:508-523.
4. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6:224ra224.
5. Crowley E., Di Nicolantonio F., Loupakis F., Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 2013, 10:472-484.
6. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
7. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 2014, 32:579-586.
8. Diaz L.A., Williams R.T., Wu J., Kinde I., Hecht J.R., Berlin J., Allen B., Bozic I., Reiter J.G., Nowak M.A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
9. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., Thornton K., Agrawal N., Sokoll L., Szabo S.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14:985-990.
10. Domagała P., Hybiak J., Sulz˙yc-Bielicka V., Cybulski C., Ryś J., Domagała W. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach. Pol. J. Pathol. 2012, 63:145-164.
11. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45:228-247.
12. Flamini E., Mercatali L., Nanni O., Calistri D., Nunziatini R., Zoli W., Rosetti P., Gardini N., Lattuneddu A., Verdecchia G.M., et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin. Cancer Res. 2006, 12:6985-6988.
13. Frattini M., Balestra D., Verderio P., Gallino G., Leo E., Sozzi G., Pierotti M.A., Daidone M.G. Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients. J. Clin. Oncol. 2005, 23:3163-3164. author reply 3164-3165.
14. Gahan P.B., Anker P., Stroun M. Metabolic DNA as the origin of spontaneously released DNA?. Ann. N. Y. Acad. Sci. 2008, 1137:7-17.
15. Haggar F.A., Boushey R.P. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin. Colon Rectal Surg. 2009, 22:191-197.
16. Heitzer E., Auer M., Hoffmann E.M., Pichler M., Gasch C., Ulz P., Lax S., Waldispuehl-Geigl J., Mauermann O., Mohan S., et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int. J. Cancer 2013, 133:346-356.
17. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61:1659-1665.
18. Keesee S.K., Briggman J.V., Thill G., Wu Y.J. Utilization of nuclear matrix proteins for cancer diagnosis. Crit. Rev. Eukaryot. Gene Expr. 1996, 6:189-214.
19. Lam N.Y., Rainer T.H., Chan L.Y., Joynt G.M., Lo Y.M. Time course of early and late changes in plasma DNA in trauma patients. Clin. Chem. 2003, 49:1286-1291.
20. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977, 37:646-650.
21. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5:845-856.
22. Ma E.S., Wong C.L., Law F.B., Chan W.K., Siu D. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J. Clin. Pathol. 2009, 62:886-891.
23. Misale S., Arena S., Lamba S., Siravegna G., Lallo A., Hobor S., Russo M., Buscarino M., Lazzari L., Sartore-Bianchi A., et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 2014, 6:224ra226.
24. Misale S., Di Nicolantonio F., Sartore-Bianchi A., Siena S., Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014, 4:1269-1280.
25. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., Valtorta E., Schiavo R., Buscarino M., Siravegna G., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
26. Mohan S., Heitzer E., Ulz P., Lafer I., Lax S., Auer M., Pichler M., Gerger A., Eisner F., Hoefler G., et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 2014, 10:e1004271.
27. Mouliere F., El Messaoudi S., Gongora C., Guedj A.S., Robert B., Del Rio M., Molina F., Lamy P.J., Lopez-Crapez E., Mathonnet M., et al. Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load. Transl. Oncol. 2013, 6:319-328.
28. Pantel K., Alix-Panabières C. Real-time liquid biopsy in cancer patients: fact or fiction?. Cancer Res. 2013, 73:6384-6388.
29. Pantel K., Diaz L.A., Polyak K. Tracking tumor resistance using 'liquid biopsies'. Nat. Med. 2013, 19:676-677.
30. Reinert T., Schøler L.V., Thomsen R., Tobiasen H., Vang S., Nordentoft I., Lamy P., Kannerup A.S., Mortensen F.V., Stribolt K., et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 2015 Feb 4, pii: gutjnl-2014-308859, [Epub ahead of print]. http://dx.doi.org/10.1136/gutjnl-2014-308859.
31. Rykova E.Y., Morozkin E.S., Ponomaryova A.A., Loseva E.M., Zaporozhchenko I.A., Cherdyntseva N.V., Vlassov V.V., Laktionov P.P. Cell-free and cell-bound circulating nucleic acid complexes: mechanisms of generation, concentration and content. Expert Opin. Biol. Ther. 2012, 12(Suppl. 1):S141-S153.
32. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
33. Siegel R., Desantis C., Jemal A. Colorectal cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:104-117.
34. Siravegna G., Bardelli A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol. 2014, 15:449.
35. Siravegna G., Mussolin B., Buscarino M., Corti G., Cassingena A., Crisafulli G., Ponzetti A., Cremolini C., Amatu A., Lauricella C., et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 2015, 21:795-801.
36. Spindler K.L., Pallisgaard N., Andersen R.F., Brandslund I., Jakobsen A. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS One 2015, 10:e0108247.
37. Stroun M., Lyautey J., Lederrey C., Olson-Sand A., Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta 2001, 313:139-142.
38. Stroun M., Maurice P., Vasioukhin V., Lyautey J., Lederrey C., Lefort F., Rossier A., Chen X.Q., Anker P. The origin and mechanism of circulating DNA. Ann. N. Y. Acad. Sci. 2000, 906:161-168.
39. Sun L., Wu H., Guan Y.S. Colonography by CT, MRI and PET/CT combined with conventional colonoscopy in colorectal cancer screening and staging. World J. Gastroenterol. 2008, 14:853-863.
40. Thierry A.R., Mouliere F., El Messaoudi S., Mollevi C.E., L.-C., Gillet B., Gongora C., Dechelotte P., Robert B., Del Rio M., et al. Detection of KRAS and BRAF point mutations from circulating DNA analysis and concordance with tumor-tissue analysis in metastatic colorectal cancer. Nat. Med. 2014 Apr, 20(4):430-435.
41. Thierry A.R., Mouliere F., El Messaoudi S., Mollevi C., Lopez-Crapez E., Rolet F., Gillet B., Gongora C., Dechelotte P., Robert B., et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med. 2014, 20:430-435.
42. Tie J., Kinde I., Wang Y., Wong H.L., Roebert J., Christie M., Tacey M., Wong R., Singh M., Karapetis C.S., et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol. 2015.
43. Umetani N., Kim J., Hiramatsu S., Reber H.A., Hines O.J., Bilchik A.J., Hoon D.S. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem. 2006, 52:1062-1069.
44. Van Emburgh B.O., Sartore-Bianchi A., Di Nicolantonio F., Siena S., Bardelli A. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol. Oncol. 2014, 8:1084-1094.
45. Vukobrat-Bijedic Z., Husic-Selimovic A., Sofic A., Bijedic N., Bjelogrlic I., Gogov B., Mehmedovic A. Cancer antigens (CEA and CA 19-9) as markers of advanced stage of colorectal carcinoma. Med. Arch. 2013, 67:397-401.